IP Library › Granted Patent US 12,297,428
Granted Patent B2
US 12,297,428 · App. 17/264,691 · Granted May 13, 2025

Compositions for identification of membrane targets for enhancement of T cell activity against cancer

Inventors: Sidi Chen (Milford, CT); Lupeng Ye (New Haven, CT); Jonathan Park (Scott AFB, IL); Matthew Dong (San Francisco, CA); Ryan D. Chow (San Jose, CA)
Assignee: Yale University
C12N15/111A61K40/11A61K40/31A61K40/42A61K40/4204C12N15/90A61K2239/31A61K2239/47C12N2310/20C12N2800/90C12Y204/01155C12Y503/04001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,428
App. No.
17/264,691
Granted
May 13, 2025
Kind
B2
Abstract

The present invention includes compositions and methods for identification of membrane targets for enhancement of T cell activity against a disease, disorder or condition, and/or enhancing T cell anti-tumor activity in a subject in need thereof. In some embodiments, the disease is cancer. In further embodiments, the cancer is glioblastoma (GBM) or breast cancer.

Claims (1)

1. An adeno-associated virus (AAV) vector comprising the nucleic acid sequence set forth in SEQ ID NO: 69,821.

Continuity (3)
Provisional Application 62805585 · Feb 14, 2019
Provisional Application 62713217 · Aug 1, 2018
Related Publication 20220340898A1 · Oct 27, 2022
References Cited (63)
US 20090178153A1 · Gaitanaris · 2009 [cited by applicant]
US 20130004983A1 · Matsunami · 2013 [cited by examiner]
US 20160355806A1 · Lee · 2016 [cited by applicant]
US 20180156800A1 · Lin · 2018 [cited by examiner]
WO WO2013173652A1 · 2013 [cited by examiner]
WO 2017046259 · 2017 [cited by applicant]
WO WO2017046259A1 · 2017 [cited by examiner]
WO 2017064566 · 2017 [cited by applicant]
WO WO2018195073A2 · 2018 [cited by examiner]
Chow et al Nat Neurosci vol. 20 No 10 pp. 1329-1341 (pp. 1-40) (Year: 2017). [cited by examiner]
Chow et al Nature Neuroscience, 1329-1341 (Year: 2017). [cited by examiner]
Shifrut et al Cell, 175, 1958-1971 (Year: 2018). [cited by examiner]
NCBI accession No. AF287263.1, p. 1 (Year: 2001). [cited by examiner]
International Search Report and Written Opinion issued in App. No. PCT/US19/44424, mailing date Jan. 6, 2020, 18 pages. [cited by applicant]
Agarwalla, Pankaj, et al. “Sequential immunotherapy by vaccination with GM-CSF expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.” Journal of Immunotherapy (Hagerstown… [cited by applicant]
Anderson, A. C., et al. “Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.” Immunity 44.5 (2016): 989-1004. [cited by applicant]
Brown, Christine E., et al. “Regression of glioblastoma after chimeric antigen receptor T-cell therapy.” New England Journal of Medicine 375.26 (2016): 2561-2569. [cited by applicant]
Chen, Daniel S., et al. “Oncology meets immunology: the cancer-immunity cycle.” immunity 39.1 (2013): 1-10. [cited by applicant]
Chen, Runqiang, et al. “In vivo RNA interference screens identify regulators of antiviral CD4+ and CD8+ T cell differentiation.” Immunity 41.2 (2014): 325-338. [cited by applicant]
Chen, Sidi, et al. “Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis.” Cell 160.6 (2015): 1246-1260. [cited by applicant]
Dai, Hanren, et al. “Chimeric antigen receptors modified T-cells for cancer therapy.” Journal of the National Cancer Institute 108.7 (2016): djv439. [cited by applicant]
Fecci, Peter E., et al. “Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.” Clinical cancer research 13.7 (2007): 2158-2167. [cited by applicant]
Gilbert, Mark R., et al. “A randomized trial of bevacizumab for newly diagnosed glioblastoma.” New England Journal of Medicine 370.8 (2014): 699-708. [cited by applicant]
Huang, Ching-Tai, et al. “Role of LAG-3 in regulatory T cells.” Immunity 21.4 (2004): 503-513. [cited by applicant]
Ji, Seung Taek, et al. “Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering.” Stem cells international 2017 (2017). [cited by applicant]
Jiang, Peng, et al. “Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.” Nature medicine 24.10 (2018): 1550-1558. [cited by applicant]
Khalil, Danny N., et al. “The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.” Nature reviews Clinical oncology 13.5 (2016): 273-290. [cited by applicant]
Koboldt, Daniel C., et al. “VarScan: variant detection in massively parallel sequencing of individual and pooled samples.” Bioinformatics 25.17 (2009): 2283-2285. [cited by applicant]
Kvistborg, Pia, et al. “Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.” Science translational medicine 6.254 (2014): 254ra128-254ra128. [cited by applicant]
Langmead, Ben, et al. “Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.” Genome biology 10.3 (2009): 1-10. [cited by applicant]
Li, Heng, et al. “Fast and accurate short read alignment with Burrows-Wheeler transform.” bioinformatics 25.14 (2009):1754-1760. [cited by applicant]
Li, Bo, et al. “Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.” Genome biology 17.1 (2016): 1-16. [cited by applicant]
Louveau, Antoine, et al. “Structural and functional features of central nervous system lymphatics.” Nature (2015): 7560, 337-341. Author Manuscript, HHS Public Access, Available in PMC Jan. 16, 2016. doi: 10.1038/nature… [cited by applicant]
Martin, Marcel. “Cutadapt removes adapter sequences from high-throughput sequencing reads.” EMBnet. journal 17.1 (2011): 10-12. [cited by applicant]
Mates, Lajos, et al. “Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates.” Nature genetics 41.6 (2009): 753-761. [cited by applicant]
Mathios, Dimitrios, et al. “Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.” Science translational medicine 8.370 (2016): 370ra180-370ra180. Author Manuscript, HHS Public… [cited by applicant]
Mount, Christopher W., et al. “Potent antitumor efficacy of anti-GD2 Car T cells in H3-K27M+ diffuse midline gliomas.” Nature medicine 24.5 (2018): 572-579. Author Manuscript, HHS Public Access, available in PMC Nov. 2,… [cited by applicant]
Okada, Masahiro, et al. “Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells.” Cell reports 20.5 (2017): 1017-1028. [cited by applicant]
Omuro, Antonio, et al. “Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.” Neuro-oncology 20.5 (2018): 674-686. [cited by applicant]
O'Rourke, Donald M., et al. “A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.” Science translational medi… [cited by applicant]
Pardoll, Drew M. “The blockade of immune checkpoints in cancer immunotherapy.” Nature reviews cancer 12.4 (2012): 252-264. [cited by applicant]
Pellegatta, Serena, et al. “Constitutive and TNFa-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.” Science translational medicine 10.430 … [cited by applicant]
Preusser, Matthias, et al. “Prospects of immune checkpoint modulators in the treatment of glioblastoma.” Nature Reviews Neurology 11.9 (2015): 504-514. [cited by applicant]
Ribas, Antoni. “Tumor immunotherapy directed at PD-1.” N Engl J Med 366.26 (2012): 2517-2519. [cited by applicant]
Ribas, Antoni, et al. “Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.” The lancet oncology 16.8 (2015): 908-918. [cited by applicant]
Saha, Dipongkor, et al. “Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade.” Cancer cell 32.2 (2017): 253-267. [cited by applicant]
Shalem, Ophir, et al. “Genome-scale CRISPR-Cas9 knockout screening in human cells.” Science 343.6166 (2014): 84-87. [cited by applicant]
Shibui, Akiko, et al. “Alteration of immune responses by N-acetylglucosaminyltransferase V during allergic airway inflammation.” Allergology International 60.3 (2011): 345-354. [cited by applicant]
Shifrut, Eric, et al. “Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function.” Cell 175.7 (2018): 1958-1971. [cited by applicant]
Smith, Logan K., et al. “Interleukin-10 directly inhibits CD8+ T cell function by enhancing N-glycan branching to decrease antigen sensitivity.” Immunity 48.2 (2018): 299-312. [cited by applicant]
Sugiura, Kanematsu, C., et al. “Studies in a tumor spectrum. II. The growth of a variety of mouse and rat tumors.” Cancer 5.5 (1952): 979-991. [cited by applicant]
Tumeh, Paul C., et al. “PD-1 blockade induces responses by inhibiting adaptive immune resistance.” Nature 515.7528 (2014): 568-571. [cited by applicant]
Wang, Guangchuan, et al. “Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR—mediated direct in vivo screening.” Science advances 4.2 (2018): eaao5508. [cited by applicant]
Weller, Michael, et al. “EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.” The lancet oncology 15.9 (2014): e395-e403. [cited by applicant]
Workman, Creg J., et al. “Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3.” The Journal of Immunology 169.10 (2002): 5392-5395. [cited by applicant]
Workman, Creg J., et al. “Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.” The Journal of Immunology 172.9 (2004): 5450-5455. [cited by applicant]
Zhou, Penghui, et al. “In vivo discovery of immunotherapy targets in the tumour microenvironment.” Nature 506.7486 (2014): 52-57. [cited by applicant]
Hogquist, K.A., et al., “T-Cell Receptor Antagonist Peptides Induce Positive Selection”. Cell 76, 17-27 (1994). [cited by applicant]
Schlager, C., et al., “Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid”, Nature 530, 349-+ (2016). [cited by applicant]
Bernards, R., “Finding effective cancer therapies through loss of function genetic screens”, Current Opinion in Genetics & Development 24, 23-29 (2014). [cited by applicant]
Ting, P.Y., et al., “Guide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells”, Nat Methods 15, 941-946 (2018). [cited by applicant]
Demetriou, M., et al., “Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation”, Nature 409, 733-739 (2001). [cited by applicant]
Granovsky, M., et al., “Suppression of tumor growth and metastasis in Mgat5-deficient mice.”, Nat Med 6, 306-312 (2000). [cited by applicant]